000172267 000__ 01098mam\a2200301\a\4500
000172267 001__ 172267
000172267 005__ 20210513054557.0
000172267 008__ 890314s1989\\\\paua\\\\\b\\\\001\0\eng\d
000172267 035__ $$a(OCoLC)ocm19363489
000172267 035__ $$a172267
000172267 040__ $$aFHJ$$cFHJ$$dNGU
000172267 049__ $$aISEA
000172267 090__ $$aRC60$$b.M4 v.73, no. 2
000172267 24500 $$aCardiovascular pharmacotherapy III /$$cWilliam H. Frishman and Shlomo Charlap, guest editors.
000172267 260__ $$aPhiladelphia :$$bSaunders,$$c1989.
000172267 300__ $$axiv, p. 271-516 :$$bill. ;$$c24 cm.
000172267 4901_ $$aMedical clinics of North America ;$$vv. 73, no. 2
000172267 500__ $$a"March 1989"
000172267 504__ $$aIncludes bibliographical references and index.
000172267 650_0 $$aCardiovascular agents.
000172267 650_0 $$aCardiovascular system$$xDiseases$$xChemotherapy.
000172267 650_0 $$aCongestive heart failure$$xChemotherapy.
000172267 650_0 $$aMyocardial infarction$$xChemotherapy.
000172267 7001_ $$aFrishman, William H.,$$d1946-
000172267 7001_ $$aCharlap, Shlomo.
000172267 7400_ $$aCardiovascular pharmacotherapy three.
000172267 7400_ $$aCardiovascular pharmacotherapy 3.
000172267 830_0 $$aMedical clinics of North America ;$$vv. 73, no. 2.
000172267 85200 $$bgen$$hRC60$$i.M4$$iv.73$$ino.2
000172267 909CO $$ooai:library.usi.edu:172267$$pGLOBAL_SET
000172267 980__ $$aBIB
000172267 980__ $$aBOOK